AstraZeneca BD Head Says More Out-Licensing, Divestment Expected In 2016
This article was originally published in Scrip
Executive Summary
AstraZeneca PLC says it remains committed to developing medicines across small molecules, biologics, vaccines, protein engineering and devices and that's what its future targeted business development strategy will pursue.
You may also be interested in...
Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar
Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
AstraZeneca's first-half results presentation highlighted its growing early pipeline, notably in oncology, but also the increasing pain of generic erosion on its Crestor sales – underlining again the importance new drugs will play in the group's turnaround strategy.